Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Abstract 3845: A matching panel of tumor organoids and patient derived orthotopic xenograft mouse models (PDOX) of high-grade gliomas in EGFP-based SCID mice

Xin (Alice) Zhai, Milagros Suarez Palacios, Zilu Huang, Jinnan Chen, Tongchao Jiang, Nitin Wadhwani, Michael DeCuypere, Yuchen Du, Xiaonan Li

Cancer Res (2025) 85 (8_Supplement_1): 3845.

https://doi.org/10.1158/1538-7445.AM2025-3845

Published: 21 April 2025

View articletitled, Abstract 3845: A matching panel of tumor organoids and patient derived orthotopic xenograft mouse models (PDOX) of high-grade gliomas in EGFP-based SCID mice

Journal Articles

Abstract PO3-26-10: Small molecule inhibitor of PELP1 exhibit cytotoxic effects on breast cancer cells by blocking ribosome biogenesis

Xue Yang, Khaled Mohamed Nassar, Uday Pratap, Rahul Gopalam, Behnam Ebrahimi, Durga Meenakshi Panneerdoss, Xiaonan Li, Yaxia Yuan, Daohong Zhou, Gangadhara R. Sareddy, Rajeshwar R. Tekmal, Manjeet Rao, Suryavathi Viswanadhapalli, Ratna Vadlamudi

Cancer Res (2024) 84 (9_Supplement): PO3-26-10.

https://doi.org/10.1158/1538-7445.SABCS23-PO3-26-10

Published: 02 May 2024

View articletitled, Abstract PO3-26-10: Small molecule inhibitor of PELP1 exhibit cytotoxic effects on breast cancer cells by blocking ribosome biogenesis

Journal Articles

Abstract 5998: Pharmacological inhibition of the LIF-LIFR autocrine loop reveals vulnerability of ovarian cancer to ferroptosis

Cancer Res (2024) 84 (6_Supplement): 5998.

https://doi.org/10.1158/1538-7445.AM2024-5998

Published: 22 March 2024

View articletitled, Abstract 5998: Pharmacological inhibition of the LIF-LIFR autocrine loop reveals vulnerability of ovarian cancer to ferroptosis

Journal Articles

Abstract 440: The role of PELP1 inhibitor SMIP34 in the treatment of endometrial cancer

Xue Yang, Zexuan Liu, Weiwei Tang, Uday P. Pratap, Alexia B. Collier, Kristin A. Alwegg, Nicole Spencer, Xiaonan Li, Philip T. Valente, Edward R. Kost, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi

Cancer Res (2023) 83 (7_Supplement): 440.

https://doi.org/10.1158/1538-7445.AM2023-440

Published: 04 April 2023

View articletitled, Abstract 440: The role of PELP1 inhibitor SMIP34 in the treatment of endometrial cancer

Journal Articles

Abstract 4966: Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapy

Behnam Ebrahimi, Suryavathi Viswanadhapalli, Uday P. Pratap, Rahul Gopalam, Xue Yang, Bindhu Santhamma, Swapna Konda, Xiaonan Li, Hui Yan, Gangadhara R. Sareddy, Zhenming Xu, Edward R. Kost, Rajeshwar R. Tekmal, Hareesh B. Nair, Ratna K. Vadlamudi

Cancer Res (2023) 83 (7_Supplement): 4966.

https://doi.org/10.1158/1538-7445.AM2023-4966

Published: 04 April 2023

View articletitled, Abstract 4966: Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapy

Journal Articles

A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER⁺ Breast Cancer

Cancer Res (2022) 82 (20): 3830–3844.

https://doi.org/10.1158/0008-5472.CAN-22-0698

Published: 17 October 2022

View articletitled, A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract 5341: Mechanisms driving resistance in Group 3 and recurrent/disseminated medulloblastoma

Shiying Huang, Jie-Ling Pan, Qi Lin, YuChen Du, Jack Su, Angela Major, M. Tarek Elghetany, Kam-Man Hui, Xiaonan Li, Wan-Yee Teo

Cancer Res (2022) 82 (12_Supplement): 5341.

https://doi.org/10.1158/1538-7445.AM2022-5341

Published: 15 June 2022

View articletitled, Abstract 5341: Mechanisms driving resistance in Group 3 and recurrent/disseminated medulloblastoma

Journal Articles

Abstract P5-10-01: Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer

Suryavathi Viswanadhapalli, Uday P Pratap, Behnam Ebrahimi, Logan Blankenship, Jaitri Joshi, Zexuan Liu, Kristin A Altwegg, Xiaonan Li, Gangadhara R Sareddy, Bindu Santhamma, Swapna Konda, Manjeet Rao, Edward Kost, Rajeshwar R Tekmal, Hareesh B Nair, Ratna K Vadlamudi

Cancer Res (2022) 82 (4_Supplement): P5-10-01.

https://doi.org/10.1158/1538-7445.SABCS21-P5-10-01

Published: 15 February 2022

View articletitled, Abstract P5-10-01: Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer

Journal Articles

Abstract 1237: Preclinical evaluation of ERX-41 in triple negative breast cancer

Suryavathi Viswanadhapalli, Xihui Liu, Shi-Hong Ma, Tae-Kyung Lee, Mengxing Li, Weiwei Tang, Junhao Liu, Xiaonan Li, Gangadhara R. Sareddy, Rajeshwar Rao Tekmal, Jung-Mo Ahn, Ratna K. Vadlamudi, Ganesh V. Raj

Cancer Res (2021) 81 (13_Supplement): 1237.

https://doi.org/10.1158/1538-7445.AM2021-1237

Published: 01 July 2021

View articletitled, Abstract 1237: Preclinical evaluation of ERX-41 in triple negative breast cancer

Journal Articles

Abstract 634: Targeting metastatic brain germinoma using PDOX tumor models with sequential metastases

Shiying Huang, Sekar Karthik, Jack M Su, Qi Lin, YuChen Du, Ching C Lau, Adesina Adekunle, Angela Major, Kam-Man Hui, M. Tarek Elghetany, Xiaonan Li, Wan-Yee Teo

Cancer Res (2021) 81 (13_Supplement): 634.

https://doi.org/10.1158/1538-7445.AM2021-634

Published: 01 July 2021

View articletitled, Abstract 634: Targeting metastatic brain germinoma using PDOX tumor models with sequential metastases

Journal Articles

Abstract 733: Significance of PELP1/SETDB1 axis in endocrine therapy resistance

Zexuan Liu, Junhao Liu, Weiwei Tang, Uday P. Pratap, Kristin A. Altwegg, Behnam Ebrahimi, Xiaonan Li, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi

Cancer Res (2021) 81 (13_Supplement): 733.

https://doi.org/10.1158/1538-7445.AM2021-733

Published: 01 July 2021

View articletitled, Abstract 733: Significance of PELP1/SETDB1 axis in endocrine therapy resistance

Journal Articles

Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359

Weiwei Tang, Kumaraguruparan Ramasamy, Sureshkumar M. Pillai, Bindu Santhamma, Swapna Konda, Prabhakar P. Vekata, Logan Blankenship, Junhao Liu, Zexuan Liu, Kristin A. Altwegg, Behnam Ebrahimi, Uday P. Pratap, Xiaonan Li, Edward Kost, Gangadhara R. Sareddy, Ratna K. Vadlamudi, Hareesh B. Nair, Rajeshwar R. Tekmal, Suryavathi Viswanadhapalli

Cancer Res (2021) 81 (13_Supplement): 1253.

https://doi.org/10.1158/1538-7445.AM2021-1253

Published: 01 July 2021

View articletitled, Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359

Journal Articles

Abstract PS17-34: Proto-oncogene PELP1 interactions with SETDB1 contribute to aberrant activation of AKT1 in breast cancer

Zexuan Liu, Junhao Liu, Weiwei Tang, Uday P. Pratap, Kristin A. Altwegg, Xiaonan Li, Suryavathi Viswanadhapalli, Ratna Vadlamudi

Cancer Res (2021) 81 (4_Supplement): PS17-34.

https://doi.org/10.1158/1538-7445.SABCS20-PS17-34

Published: 15 February 2021

View articletitled, Abstract PS17-34: Proto-oncogene PELP1 interactions with SETDB1 contribute to aberrant activation of AKT1 in breast cancer

Journal Articles

Abstract 4371: PELP1-TFAP2C crosstalk promotes endocrine resistance in breast cancer cells

Junhao Liu, Suryavathi Viswanadhapalli, Mengxing Li, Uday P. Pratap, Weiwei Tang, Zexuan Liu, Yiliao Luo, Kristin A. Altwegg, Xiaonan Li, Gangadhara R. Sareddy, Rajeshwar R. Tekmal, Ratna K. Vadlamudi

Cancer Res (2020) 80 (16_Supplement): 4371.

https://doi.org/10.1158/1538-7445.AM2020-4371

Published: 15 August 2020

View articletitled, Abstract 4371: PELP1-TFAP2C crosstalk promotes endocrine resistance in breast cancer cells

Journal Articles

Abstract 6220: KDM1A inhibition sensitizes glioblastoma cells to temozolomide therapy through DNA damage and apoptosis pathway modulation

Bridgitte E. Palacios, Prabhakar Pitta Venkata, Yihong Chen, Salvador Alejo, Yi He, Suryavathi Viswanadhapalli, Uday Pratap, Junhao Liu, Xiaonan Li, Takayoshi Suzuki, Siyuan Zheng, Andrew Brenner, Ratna Vadlamudi, Gangadhara Sareddy

Cancer Res (2020) 80 (16_Supplement): 6220.

https://doi.org/10.1158/1538-7445.AM2020-6220

Published: 15 August 2020

View articletitled, Abstract 6220: KDM1A inhibition sensitizes glioblastoma cells to temozolomide therapy through DNA damage and apoptosis pathway modulation

Journal Articles

Abstract 562: Novel combination therapy for treating TNBC using LIFR and HDAC Inhibitors

Suryavathi Viswanadhapalli, Mengxing Li, Bindu Santhamma, Uday P. Pratap, Yiliao Luo, Junhao Liu, Kristin A. Altwegg, Xiaonan Li, Ahmed Gulzar, Hui Yan, Zhenming Xu, Andrew Brenner, Gangadhara R. Sareddy, Manjeet K. Rao, Rajeshwar R. Tekmal, Hareesh B. Nair, Klaus J. Nickisch, Ratna K. Vadlamudi

Cancer Res (2020) 80 (16_Supplement): 562.

https://doi.org/10.1158/1538-7445.AM2020-562

Published: 15 August 2020

View articletitled, Abstract 562: Novel combination therapy for treating TNBC using LIFR and HDAC Inhibitors

Journal Articles

Abstract P3-11-08: Targeting LIFR enhances the activity of HDAC inhibitors for the treatment of triple negative breast cancer

Suryavathi Viswanadhapalli, Mengxing Li, Bindu Santhamma, Uday P Pratap, Yiliao Luo, Junhao Liu, Kristin A Altwegg, Xiaonan Li, Hui Yan, Zhenming Xu, Andrew Brenner, Gangadhara R Sareddy, Rajeshwar R Tekmal, Hareesh B Nair, Klaus J Nickisch, Ratna K Vadlamudi

Cancer Res (2020) 80 (4_Supplement): P3-11-08.

https://doi.org/10.1158/1538-7445.SABCS19-P3-11-08

Published: 15 February 2020

View articletitled, Abstract P3-11-08: Targeting LIFR enhances the activity of HDAC inhibitors for the treatment of triple negative breast cancer

Journal Articles

Abstract P6-04-14: The role of PELP1-TFAP2C crosstalk in mediating endocrine-therapy-resistance in breast cancer

Junhao Liu, Suryavathi Viswanadhapalli, Mengxing Li, Uday P Pratap, Yiliao Luo, Kristin A Altwegg, Xiaonan Li, Gangadhara R Sareddy, Rajeshwar R Tekmal, Ratna K Vadlamudi

Cancer Res (2020) 80 (4_Supplement): P6-04-14.

https://doi.org/10.1158/1538-7445.SABCS19-P6-04-14

Published: 15 February 2020

View articletitled, Abstract P6-04-14: The role of PELP1-TFAP2C crosstalk in mediating endocrine-therapy-resistance in breast cancer

Journal Articles

Abstract 3485: PELP1 is a novel mediator of medulloblastoma progression

Yiliao Luo, Gangadhara Reddy Sareddy, Uday P. Pratap, Mengxing Li, Junhao Liu, Prabhakar Pitta-Venkata, Suryavathi Viswanadhapalli, Xiaonan Li, Manjeet Rao, Rajeshwar Rao Tekmal, Ratna K. Vadlamudi

Cancer Res (2019) 79 (13_Supplement): 3485.

https://doi.org/10.1158/1538-7445.AM2019-3485

Published: 01 July 2019

View articletitled, Abstract 3485: PELP1 is a novel mediator of medulloblastoma progression

Journal Articles

Abstract 280: Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer

Prabhakar Pitta-Venkata, Bridgitte Palacios, Yihong Chen, Suryavathi Viswanadhapalli, Uday P. Pratap, Yiliao Luo, Mengxing Li, Kristin Altwegg, Xiaonan Li, Takayoshi Suzuki, Rajeshwar Rao Tekmal, Edward Kost, Gangadhara Reddy Sareddy

Cancer Res (2019) 79 (13_Supplement): 280.

https://doi.org/10.1158/1538-7445.AM2019-280

Published: 01 July 2019

View articletitled, Abstract 280: Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 3845: A matching panel of tumor organoids and patient derived orthotopic xenograft mouse models (PDOX) of high-grade gliomas in EGFP-based SCID mice

Abstract PO3-26-10: Small molecule inhibitor of PELP1 exhibit cytotoxic effects on breast cancer cells by blocking ribosome biogenesis

Abstract 5998: Pharmacological inhibition of the LIF-LIFR autocrine loop reveals vulnerability of ovarian cancer to ferroptosis

Abstract 440: The role of PELP1 inhibitor SMIP34 in the treatment of endometrial cancer

Abstract 4966: Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapy

A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER⁺ Breast Cancer

Abstract 5341: Mechanisms driving resistance in Group 3 and recurrent/disseminated medulloblastoma

Abstract P5-10-01: Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer

Abstract 1237: Preclinical evaluation of ERX-41 in triple negative breast cancer

Abstract 634: Targeting metastatic brain germinoma using PDOX tumor models with sequential metastases

Abstract 733: Significance of PELP1/SETDB1 axis in endocrine therapy resistance

Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359

Abstract PS17-34: Proto-oncogene PELP1 interactions with SETDB1 contribute to aberrant activation of AKT1 in breast cancer

Abstract 4371: PELP1-TFAP2C crosstalk promotes endocrine resistance in breast cancer cells

Abstract 6220: KDM1A inhibition sensitizes glioblastoma cells to temozolomide therapy through DNA damage and apoptosis pathway modulation

Abstract 562: Novel combination therapy for treating TNBC using LIFR and HDAC Inhibitors

Abstract P3-11-08: Targeting LIFR enhances the activity of HDAC inhibitors for the treatment of triple negative breast cancer

Abstract P6-04-14: The role of PELP1-TFAP2C crosstalk in mediating endocrine-therapy-resistance in breast cancer

Abstract 3485: PELP1 is a novel mediator of medulloblastoma progression

Abstract 280: Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only